 Home > Active Ingredient News > Blood System > Clin Cancer Res: Long-term prognosis of rituximab+lenalidomide→lenalidomide in the treatment of indolent non-Hodgkin’s lymphoma

Clin Cancer Res: Long-term prognosis of rituximab+lenalidomide→lenalidomide in the treatment of indolent non-Hodgkin’s lymphoma

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

long plastic spoons

motion analysis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Rituximab and lenalidomide are effective against previously untreated relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)

Lymphoma

Researchers such as Tuscano conducted two open-label phase II trials that included 60 previously untreated and R/R advanced iNHL patients

PFS and OS of patients in the untreated cohort (A) and R/R cohort (B)

The median follow-up time of untreated advanced iNHL patients and R/R advanced iNHL patients was 63 months and 100 months, respectively; the ORR of both groups was 82%

The ORR of the two groups of patients was 82% .

Granzyme B ⁺ (GranB ⁺ ) of CD8 ⁺ there is a significant correlation between T cells and long-term complete remission (LTCR) between granzyme B ⁺ (GranB ⁺ ) of CD8 ⁺ presence of T cells and long-term complete remission (LTCR) between significant correlation ⁺⁺⁺⁺⁺

In summary, for previously untreated and R/R iNHL patients, rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable

For previously untreated and R/R iNHL patients, rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable for previously untreated and R/R iNHL patients , Rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable ⁺⁺

Original source:

Joseph M.

Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed / Refractory Indolent Lymphoma

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.